{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:16:14Z","timestamp":1791335774373,"version":"4.3.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010120","name":"Huashan Hospital","doi-asserted-by":"publisher","award":["HSBY2020008"],"award-info":[{"award-number":["HSBY2020008"]}],"id":[{"id":"10.13039\/501100010120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["22ZR1409300"],"award-info":[{"award-number":["22ZR1409300"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103640"],"award-info":[{"award-number":["82103640"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.wneu.2022.11.050","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T09:24:35Z","timestamp":1668417875000},"page":"e500-e509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Clinical Outcomes of Patients with Epidermal Growth Factor Receptor\u2013Mutated Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis in the Modern Target Therapy Era"],"prefix":"10.1016","volume":"170","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2022.11.050_bib1","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.wneu.2022.11.050_bib2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"The New Engl J Med"},{"key":"10.1016\/j.wneu.2022.11.050_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.lungcan.2012.05.092","article-title":"Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation","volume":"77","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.wneu.2022.11.050_bib6","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis","volume":"10","author":"Liao","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib7","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib8","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/cncr.21033","article-title":"High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib","volume":"103","author":"Omuro","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.wneu.2022.11.050_bib9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","article-title":"Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer","volume":"70","author":"Togashi","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.wneu.2022.11.050_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10637-010-9569-1","article-title":"Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP","volume":"30","author":"de Vries","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.wneu.2022.11.050_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.wneu.2022.11.050_bib12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","article-title":"Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib13","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/JTO.0b013e3181b62572","article-title":"Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib","volume":"4","author":"Katayama","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JTO.0000000000000380","article-title":"Efficacy of the Irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)\u2013pretreated non\u2013small-cell lung cancer patients with brain metastases or leptomeningeal disease","volume":"10","author":"Hoffknecht","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib15","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"\u201cPulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro Oncol"},{"issue":"suppl_4","key":"10.1016\/j.wneu.2022.11.050_bib16","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib17","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/1759-7714.13296","article-title":"Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor","volume":"11","author":"Kwon","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.wneu.2022.11.050_bib18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","article-title":"Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis","volume":"15","author":"Ahn","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"Supplement_2","key":"10.1016\/j.wneu.2022.11.050_bib19","article-title":"105OOsimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: the AURA LM study","volume":"30","author":"Ahn","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib20","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","article-title":"Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era","volume":"76","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.wneu.2022.11.050_bib22","doi-asserted-by":"crossref","first-page":"723562","DOI":"10.3389\/fonc.2021.723562","article-title":"Survival outcomes of patients with epidermal growth factor receptor mutations in non-small cell lung cancer with leptomeningeal metastasis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib23","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/1759-7714.13123","article-title":"Prognostic significance of molecular characteristics of cerebrospinal fluid for non-small cell lung cancer patients with leptomeningeal metastasis","volume":"10","author":"Li","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.wneu.2022.11.050_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","article-title":"Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis","volume":"89","author":"Kuiper","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.wneu.2022.11.050_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13014-020-01627-y","article-title":"Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study","volume":"15","author":"Zhen","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib26","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/neuonc\/noq076","article-title":"EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer","volume":"12","author":"Eichler","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib27","doi-asserted-by":"crossref","first-page":"9251","DOI":"10.1007\/s13277-015-3653-2","article-title":"Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer","volume":"36","author":"Li","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.wneu.2022.11.050_bib28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2012.03.002","article-title":"Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group","volume":"77","author":"Umemura","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.wneu.2022.11.050_bib29","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","article-title":"Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib","volume":"12","author":"Jackman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2022.11.050_bib30","first-page":"100322","article-title":"Overall survival benefits of first-line treatments for Asian patients with advanced EGFR-mutated NSCLC harboring L858R mutation: a systematic review and network meta-analysis","volume":"3","author":"Chan","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.wneu.2022.11.050_bib31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JTO.0b013e318287c943","article-title":"Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer","volume":"8","author":"Gwak","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.lungcan.2008.11.017","article-title":"Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer","volume":"65","author":"Kim","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.wneu.2022.11.050_bib33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13014-019-1376-z","article-title":"Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis","volume":"14","author":"Yan","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11523-018-0581-2","article-title":"Efficacy of Osimertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastases pretreated with EGFR-tyrosine kinase inhibitors","volume":"13","author":"Saboundji","year":"2018","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.wneu.2022.11.050_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to Osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with Untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J\u00a0Clin Oncol"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875022016035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875022016035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:21:26Z","timestamp":1761816086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875022016035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":35,"alternative-id":["S1878875022016035"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2022.11.050","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes of Patients with Epidermal Growth Factor Receptor\u2013Mutated Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis in the Modern Target Therapy Era","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2022.11.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}